(Q34979814)

5 August 2017

0 references

1 reference

title

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis (English)

1 reference

5 August 2017

0 references

1 reference

1 reference

1 reference

Berghmans T

1

1 reference

5 August 2017

Paesmans M

2

1 reference

5 August 2017

Lalami Y

3

1 reference

5 August 2017

Louviaux I

4

1 reference

5 August 2017

Luce S

5

1 reference

5 August 2017

Mascaux C

6

1 reference

5 August 2017

Meert AP

7

1 reference

5 August 2017

Sculier JP

8

1 reference

5 August 2017

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

38

1 reference

5 August 2017

2

1 reference

5 August 2017

111-121

1 reference

Chemotherapy in malignant pleural mesothelioma. A review.

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Clinical aspects of malignant mesothelioma in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A review of chemotherapy trials for malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Maintenance chemotherapy for small cell lung cancer: a critical review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Weekly high-dose cisplatin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Caelyx in malignant mesothelioma: a phase II EORTC study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Phase II study of intravenous Doxil in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A phase II study of the platinum analogues JM8 and JM9 in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Phase II trial of carboplatin in the management of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A prospective study of detorubicin in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)--Mesothelioma Committee.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A phase II study of pirarubicin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Menogaril in the treatment of malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Ifosfamide in malignant mesothelioma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Two dose levels of ifosfamide in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A phase II study of m-AMSA in patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A phase II study of vincristine in malignant mesothelioma--a negative report

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Oral etoposide in the treatment of malignant mesothelioma. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Phase II trial of topotecan for the treatment of mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma--a feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Effect of interferon-alpha 2a on malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

Do authors of review articles use systematic methods to identify, assess and synthesize information?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900180-0

7 January 2021

10.1016/S0169-5002(02)00180-0

Identifiers

DOI

1 reference

release_ys6ot5lndzbwff3dmdityalmsu

5 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ys6ot5lndzbwff3dmdityalmsu

24 November 2022

mapped directly with Wikidata item

1 reference